Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Profit After Tax (2016 - 2023)

Historic Profit After Tax for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $101.2 million.

  • RedHill Biopharma's Profit After Tax rose 29186.8% to $101.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$40.0 million, marking a year-over-year increase of 7561.85%. This contributed to the annual value of -$8.3 million for FY2024, which is 13457.1% down from last year.
  • As of Q2 2023, RedHill Biopharma's Profit After Tax stood at $101.2 million, which was up 29186.8% from -$50.2 million recorded in Q1 2023.
  • RedHill Biopharma's Profit After Tax's 5-year high stood at $101.2 million during Q2 2023, with a 5-year trough of -$145.2 million in Q4 2021.
  • For the 5-year period, RedHill Biopharma's Profit After Tax averaged around -$4.2 million, with its median value being $11.1 million (2019).
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 106284.39% in 2021, then surged by 29186.8% in 2023.
  • RedHill Biopharma's Profit After Tax (Quarter) stood at $11.8 million in 2019, then grew by 27.44% to $15.1 million in 2020, then tumbled by 1062.84% to -$145.2 million in 2021, then surged by 52.14% to -$69.5 million in 2022, then surged by 245.63% to $101.2 million in 2023.
  • Its Profit After Tax stands at $101.2 million for Q2 2023, versus -$50.2 million for Q1 2023 and -$69.5 million for Q4 2022.